ПРЕПРИНТ
О результатах, изложенных в препринтах, не следует сообщать в СМИ как о проверенной информации.
Potential health damage due to asbestos exposure has been evaluated using information from the mid 20th century and earlier, when exposures of workers and residents were greater. A linear no-threshold model has been applied, although its relevance is unproven. The fibers get into the air due to erosion of surface deposits and industries unrelated to asbestos. If looked for, the fibers are often found post mortem. The research is associated with bias: attributing malignancy to asbestos when fibers are found, although causality remains unproven. A history of exposure does not necessarily prove a cause-effect relationship. Asbestos bans enhance damage from fires and accidents. Potential toxicity of serpentine and amphibole asbestos is analyzed here. Many animal experiments indicate similar level of toxicity; while epidemiological studies of humans witness in favor of higher toxicity of amphiboles. This can be partly attributed to a bias in the latter study type. Epidemiological research in humans will not provide much information on low-dose impact. Reliable results can be obtained in large-scale lifelong bioassays with inhalation of fibers comparable to professional exposures.
Jargin S. 2026. Asbestos and anti-asbestos campaign: medical and economical aspects. PREPRINTS.RU. https://doi.org/10.24108/preprints-3114639
1. Jargin SV. Overestimation of medical consequences of increased radiation background. Medical Radiology and radiation safety 2008;53(3):17-22.
2. Jargin SV. On the biological effects of radiofrequency electromagnetic fields. Siberian Scientific Medical Journal. 2019;39(5):52-61.
3. Paustenbach D, Brew D, Ligas S, Heywood J. A critical review of the 2020 EPA risk assessment for chrysotile and its many shortcomings. Crit Rev Toxicol. 2021;51:509-539.
4. Noonan CW. Environmental asbestos exposure and risk of mesothelioma. Ann Transl Med. 2017.5(11):234.
5. Ilgren E, Van Orden DR, Lee RJ, Kamiya YM, Hoskins JA. Further studies of Bolivian crocidolite - Part IV: Fibre width, fibre drift and their relation to mesothelioma Induction: Preliminary Findings. Epidemiology Biostatistics and Public Health. 2015;12:e11167-11161.
6. Casali M, Carugno M, Cattaneo A, Consonni D, Mensi C, et al. Asbestos lung burden in necroscopic samples from the general population of Milan, Italy. Ann Occup Hyg. 2015;59:909-921.
7. Bayram M, Bakan ND. Environmental exposure to asbestos: from geology to mesothelioma. Curr Opin Pulm Med. 2014;20:301-307.
8. Yang H, Testa JR, Carbone M. Mesothelioma epidemiology, carcinogenesis, and pathogenesis. Curr Treat Options Oncol. 2008;9:147-157.
9. Wolff H, Vehmas T, Oksa P, Rantanen J, Vainio H. Asbestos, asbestosis, and cancer, the Helsinki Criteria for Diagnosis and Attribution 2014: Recommendations. Scand J Work Environ Health. 2015;41:5-15.
10. Tran T, Egilman D, Rigler M, Emory T. A critique of Helsinki Criteria for using lung fiber levels to determine causation in mesothelioma cases. Ann Glob Health. 2021;87(1):73.
11. Janosikova M, Nakladalova M, Stepanek L. Current causes of mesothelioma: how has the asbestos ban changed the perspective? Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2023;167(2):99-108.
12. Febres-Aldana CA, Fanaroff R, Offin M, Zauderer MG, Sauter JL, Yang SR, Ladanyi M. Diffuse pleural mesothelioma: advances in molecular pathogenesis, diagnosis, and treatment. Annu Rev Pathol. 2024;19:11-42.
13. Røe OD, Stella GM. Malignant pleural mesothelioma: history, controversy and future of a manmade epidemic. Eur Respir Rev. 2015;24:115-131.
14. Berry TA, Belluso E, Vigliaturo R, Gieré R, Emmett EA, Testa JR, et al. Asbestos and other hazardous fibrous minerals: potential exposure pathways and associated health risks. Int J Environ Res Public Health. 2022;19(7):4031.
15. Carbone M, Adusumilli PS, Alexander HR Jr, Baas P, Bardelli F, et al. Mesothelioma: Scientific clues for prevention, diagnosis, and therapy. CA Cancer J Clin. 2019;69:402-429.
16. Kane AB, Hurt RH, Gao H. The asbestos-carbon nanotube analogy: An update. Toxicol Appl Pharmacol 2018;361:68-80.
17. Numano T, Higuchi H, Alexander DB, Alexander WT, Abdelgied M, El-Gazzar AM, et al. MWCNT-7 administered to the lung by intratracheal instillation induces development of pleural mesothelioma in F344 rats. Cancer Sci. 2019;110(8):2485-2492.
18. Nel A. Carbon nanotube pathogenicity conforms to a unified theory for mesothelioma causation by elongate materials and fibers. Environ Res. 2023;230:114580.
19. Carbone M, Gazdar A, Butel JS. SV40 and human mesothelioma. Transl Lung Cancer Res. 2020;9(Suppl 1):S47-S59.
20. Testa JR, Carbone M, Hirvonen A, Khalili K, Krynska B, Linnainmaa K, et al. A multi-institutional study confirms the presence and expression of simian virus 40 in human malignant mesotheliomas. Cancer Res. 1998;58(20):4505-4509.
21. Garcea RL, Imperiale MJ. Simian virus 40 infection of humans. J Virol. 2003;77:5039-5045.
22. Cicala C, Pompetti F, Carbone M. SV40 induces mesotheliomas in hamsters. Am J Pathol. 1993;142:1524-1533.
23. Likhacheva EI, Iarina AL, Vagina ER, Klimina MS, Obukhova TIu, et al. Clinical features of pulmonary diseases caused by chrysotile asbestos dust. Med Tr Prom Ekol. 2000;(11):30-33.
24. Milishnikova VV, Loshchilov IU, Gladkova EV, Aksenova AO, Turkina LA. Endoscopic and morphological characteristics of the bronchi and lungs in asbestosis and dust-induced bronchitis in asbestostextile industry workers. Gig Tr Prof Zabol. 1990;(7):19-22.
25. Jargin SV. Bronchoscopy with questionable indications. J Med Clin Stud. 2025;8(3):230.
26. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Arsenic, metals, fibres, and dusts. IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt C):11-465.
27. Carbone M, Yang H. Mesothelioma: recent highlights. Ann Transl Med. 2017;5(11):238.
28. Kerger BD, James RC, Galbraith DA. Tumors that mimic asbestos-related mesothelioma: Time to consider a genetics-based tumor registry? Front Genet. 2014;5:151.
29. Panou V, Vyberg M, Weinreich UM, Meristoudis C, Falkmer UG, Røe OD. The established and future biomarkers of malignant pleural mesothelioma. Cancer Treat Rev. 2015;41:486-495.
30. Chen Z, Gaudino G, Pass HI, Carbone M, Yang H. Diagnostic and prognostic biomarkers for malignant mesothelioma: an update. Transl Lung Cancer Res. 2017;6:259-269.
31. Goldberg M, Imbernon E, Rolland P, Gilg Soit Ilg A, Savès M, et al. The French national mesothelioma surveillance program. Occup Environ Med. 2006;63:390-395.
32. Lorenzini E, Ciarrocchi A, Torricelli F. Molecular fingerprints of malignant pleural mesothelioma: not just a matter of genetic alterations. J Clin Med. 2021;10(11):2470.
33. Sorino C, Mondoni M, Marchetti G, Agati S, Inchingolo R, Mei F, et al. Pleural Mesothelioma: Advances in Blood and Pleural Biomarkers. J Clin Med. 2023;12(22):7006.
34. Lu Z, Zhang W, Huang K, Zhu M, Gu X, Wei D, et al. Systematic review, meta-analysis and bioinformatic analysis of biomarkers for prognosis of malignant pleural mesothelioma. Diagnostics. (Basel). 2022;12(9):2210.
35. Harris EJA, Musk A, de Klerk N, Reid A, Franklin P, Brims FJH. Diagnosis of asbestos-related lung diseases. Expert Rev Respir Med. 2019;13(3):241-249.
36. Gee GV, Koestler DC, Christensen BC, Sugarbaker DJ, Ugolini D, et al. Downregulated microRNAs in the differential diagnosis of malignant pleural mesothelioma. Int J Cancer. 2010;127:2859-2869.
37. Reid G. MicroRNAs in mesothelioma: from tumour suppressors and biomarkers to therapeutic targets. J Thorac Dis. 2015;7:1031-1040.
38. Zahiu T, Mihu CM, Bosca BA, Mărginean M, Mocan LP, Ștefan RA, et al. Molecular insights into pleural mesothelioma: unveiling pathogenic mechanisms and therapeutic opportunities. Diagnostics (Basel). 2025;15(11):1323.
39. Rossi G, Davoli F, Poletti V, Cavazza A, Lococo F. When the diagnosis of mesothelioma challenges textbooks and guidelines. J Clin Med. 2021;10(11):2434.
40. Cersosimo F, Barbarino M, Lonardi S, Vermi W, Giordano A, Bellan C, Giurisato E. Mesothelioma malignancy and the microenvironment: molecular mechanisms. Cancers (Basel). 2021;13(22):5664.
41. Blyth KG, Murphy DJ. Progress and challenges in mesothelioma: From bench to bedside. Respir Med. 2018;134:31-41.
42. Protas SV. Hygienic evaluation of air pollution with asbestos dust in subway parkings. Med Tr Prom Ekol. 2014;(1):23-6.
43. Varivonchik DV. Epidemiologic situation in Ukraine, concerning malignant mesothelioma prevalence. Med Tr Prom Ekol. 2014;(1):18-22.
44. Nagornaia AM, Varivonchik DV, Kundiev IuI, Fedorenko ZP, Gorokh EL, Gulak LO, et al. Cancer morbidity risks among workers of asbestos-cement productions. Med Tr Prom Ekol. 2008;(3):27-33.
45. Pylev DN, Smirnova OV, Vasil'eva LA, Khrustalev SA, Vezentsev AI, et al. Experimental rationale for carcinogenic risk of asbestos cement industry and its products. Gig Sanit. 2010;(6):61-65.
46. Troitskaia NA. A comparative study of cytotoxicity of dust of carbon fibers and other fibrous materials. Gig Sanit. 1993;(3):28-30.
47. Schüz J, Kovalevskiy E, Olsson A, Moissonnier M, Ostroumova E, Ferro G, et al. Cancer mortality in chrysotile miners and millers, Russian Federation: main results (Asbest Chrysotile Cohort-Study). J Natl Cancer Inst. 2024;116(6):866-875.
48. Kogan FM, Kashanskii SV, Plotko EG, Berzin SA, Bogdanov GB. Effect of low concentration of asbestos-containing dust. Med Tr Prom Ekol. 1993;(5-6):6-10.
49. Shtol' AV, Plotko EG, Seliankina KP. Children's health and environmental air pollution with dust containing asbestos. Med Tr Prom Ekol. 2000;(11):10-13.
50. Tsurikova GV, Spitsyn VA, Gladkova EV, Minaeva OP. Biodemographic parameters as indicators of genetic adaptation to harmful occupational factors (e.g. asbestos). Gig Tr Prof Zabol. 1992;(6):28-30.
51. Kaptsov VA, Kashanskii SV, Domnin SG, Tikhova TS, Trofimova EV, Novoselova TA, Bogdanov GB. Railway use of asbestos-containing rubble: environmental hygienic aspects. Gig Sanit. 2003;(5):11-15.
52. Kashanskii SV, Domnin SG, Plotko EG, Kuz'min SV, Seliankina SV, Likhacheva EI. Contemporary problems of asbestos and prospective research directions. Med Tr Prom Ekol. 2004;(9):16-19.
53. Kovalevskii EV. Hygienic evaluation of asbestos-containing friction goods application. Med Tr Prom Ekol. 2009;(7):1-6.
54. Izmerov NF, Elovskaia LT, Milishnikova VV, Burmistrova TB, Kovalevskii EV. Chrysotile asbestos in Russia: certain results and promising research directions. Med Tr Prom Ekol. 1998;(10):1-7.
55. Kashanskii SV, Zhetpisbaev BA, Il'derbaev OZ, Ermenbai OT. Mesothelioma in the Republic of Kazakhstan: a review. Gig Sanit. 2008;(5):13-7.
56. Pylev LN. The role of modifying factors in the carcinogenic effect of asbestos and asbestos-containing dusts. Eksp Onkol. 1987;9(5):14-17.
57. Bernstein DM. The health risk of chrysotile asbestos. Curr Opin Pulm Med. 2014;20:366-370.
58. Coin PG, Roggli VL, Brody AR. Persistence of long, thin chrysotile asbestos fibers in the lungs of rats. Environ Health Perspective. 1994;102:197-199.
59. Kohyama N, Suzuki Y. Analysis of asbestos fibers in lung parenchyma, pleural plaques, and mesothelioma tissues of North American insulation workers. Ann N Y Acad Sci. 1991;643:27-52.
60. Nicholson WJ. Comparative dose-response relationships of asbestos fiber types: magnitudes and uncertainties. Ann N Y Acad Sci. 1991;643:74-84.
61. Stayner LT, Dankovic DA, Lemen RA. Occupational exposure to chrysotile asbestos and cancer risk: a review of the amphibole hypothesis. Am J Public Health. 1996;86:179-186.
62. Suzuki Y, Yuen SR. Asbestos fibers contributing to the induction of human malignant mesothelioma. Ann N Y Acad Sci. 2002;982:160-176.
63. Bernstein D, Dunnigan J, Hesterberg T, Brown R, Velasco JA, et al. Health risk of chrysotile revisited. Crit Rev Toxicol. 2013;43:154-183.
64. Pezerat H. Chrysotile biopersistence: the misuse of biased studies. Int J Occup Environ Health. 2009;15:102-106.
65. Larsen G. Experimental data on in vitro fibre solubility. IARC Sci Publ. 1989;(90):134-139.
66. Asgharian B, Owen TP, Kuempel ED, Jarabek AM. Dosimetry of inhaled elongate mineral particles in the respiratory tract: The impact of shape factor. Toxicol Appl Pharmacol. 2018;361:27-35.
67. Currie GP, Watt SJ, Maskell NA. An overview of how asbestos exposure affects the lung. BMJ. 2009;339:b3209.
68. Smith AH, Wright CC. Chrysotile asbestos is the main cause of pleural mesothelioma. Am J Ind Med. 1996;30:252-266.
69. Ramada Rodilla JM, Calvo Cerrada B, Serra Pujadas C, Delclos GL, Benavides FG. Fiber burden and asbestos-related diseases: an umbrella review. Gaceta Sanitaria. 2022;36(2):173-183.
70. Finkelstein MM. Letter to the Editor re Bernstein et al: Health risk of chrysotile revisited. Crit Rev Toxicol 2013;43(2):154-183. Crit Rev Toxicol. 2013;43(8):707-708.
71. Yu CP, Asgharian B, Pinkerton KE. Intrapulmonary deposition and retention modeling of chrysotile asbestos fibers in rats. Journal of Aerosol Science. 1991;22:757-763.
72. Dodson RF, Williams MG Jr, Corn CJ, Brollo A, Bianchi C. Asbestos content of lung tissue, lymph nodes, and pleural plaques from former shipyard workers. Am Rev Respir Dis. 1990;142:843-847.
73. Gibbs AR, Stephens M, Griffiths DM, Blight BJ, Pooley FD. Fibre distribution in the lungs and pleura of subjects with asbestos related diffuse pleural fibrosis. Br J Ind Med. 1991;48:762-770.
74. Sekido Y. Molecular pathogenesis of malignant mesothelioma. Carcinogenesis. 2013;34:1413-1419.
75. Finkelstein MM, Meisenkothen C. Malignant mesothelioma among employees of a Connecticut factory that manufactured friction materials using chrysotile asbestos. Ann Occup Hyg. 2010;54(6):692-696.
76. Frank AL. Global use of asbestos - legitimate and illegitimate issues. J Occup Med Toxicol. 2020;15:16.
77. Stayner LT, Dankovic DA, Lemen RA. Asbestos-related cancer and the amphibole hypothesis: II. Stayner and colleagues respond. Am J Publ Health. 1997;87:688.
78. Stayner LT. Canada, chrysotile and cancer: Health Canada's Asbestos International Expert Panel report. J Occup Environ Med. 2008;50(12):1327-1328.
79. Harington JS. The carcinogenicity of chrysotile asbestos. Ann N Y Acad Sci. 1991;643:465-472.
80. Wagner JC. Proceedings: Asbestos carcinogenesis. Br J Cancer. 1975;32:258-259.
81. Wagner JC, Berry G, Skidmore JW, Timbrell V. The effects of the inhalation of asbestos in rats. Br J Cancer. 1974;29:252-269.
82. Berman DW, Crump KS, Chatfield EJ, Davis JM, Jones AD. The sizes, shapes, and mineralogy of asbestos structures that induce lung tumors or mesothelioma in AF/HAN rats following inhalation. Risk Anal. 1995;15:181-195.
83. Landrigan PJ, Nicholson WJ, Suzuki Y, Ladou J. The hazards of chrysotile asbestos: a critical review. Ind Health. 1999;37:271-280.
84. Davis JM, Beckett ST, Bolton RE, Collings P, Middleton AP. Mass and number of fibres in the pathogenesis of asbestos-related lung disease in rats. Br J Cancer. 1978;37:673-688.
85. Hesterberg TW, Barrett JC. Dependence of asbestos- and mineral dust-induced transformation of mammalian cells in culture on fiber dimension. Cancer Res. 1984;44:2170-2180.
86. Hodgson JT, Darnton A. The quantitative risks of mesothelioma and lung cancer in relation to asbestos exposure. Ann Occup Hyg. 2000;44:565-601.
87. Lenters V, Vermeulen R, Dogger S, Stayner L, Portengen L, et al. A meta-analysis of asbestos and lung cancer: is better quality exposure assessment associated with steeper slopes of the exposure-response relationships? Environ Health Perspect. 2011;119:1547-1555.
88. Hodgson JT, Darnton A. Mesothelioma risk from chrysotile. Occup Environ Med. 2010;67:432.
89. Dufresne A, Bégin R, Massé S, Dufresne CM, Loosereewanich P, et al. Retention of asbestos fibres in lungs of workers with asbestosis, asbestosis and lung cancer, and mesothelioma in Asbestos township. Occup Environ Med. 1996;53:801-807.
90. Rogers AJ, Leigh J, Berry G, Ferguson DA, Mulder HB, et al. Relationship between lung asbestos fiber type and concentration and relative risk of mesothelioma. A case-control study. Cancer. 1991;67:1912-1920.
91. Bernstein D, Dunnigan J, Hesterberg T, Brown R, Legaspi Velasco JA, et al. Response to Murray M. Finkelstein, letter to the editor re Bernstein et al: Health risk of chrysotile revisited. Crit Rev Toxicol, 2013;43(2):154-183. Crit Rev Toxicol. 2013;43(8):709-10.
92. Kanarek MS. Mesothelioma from chrysotile asbestos: update. Ann Epidemiol. 2011;21:688-97.
93. IARC. Consensus report. Mechanisms of fibre carcinogenesis. IARC Sci Publ. 1996;(140):1-9.
94. Mossman BT, Lippmann M, Hesterberg TW, Kelsey KT, Barchowsky A, Bonner JC. Pulmonary endpoints (lung carcinomas and asbestosis) following inhalation exposure to asbestos. J Toxicol Environ Health B Crit Rev. 2011;14(1-4):76-121.
95. Wang J, Schlagenhauf L, Setyan A. Transformation of the released asbestos, carbon fibers and carbon nanotubes from composite materials and the changes of their potential health impacts. J Nanobiotechnology. 2017;15(1):15.
96. Berman DW, Crump KS. A meta-analysis of asbestos-related cancer risk that addresses fiber size and mineral type. Crit Rev Toxicol. 2008;38 Suppl 1:49-73.
97. Gaudino G, Xue J, Yang H. How asbestos and other fibers cause mesothelioma. Transl Lung Cancer Res. 2020;9(Suppl 1):S39-46.
98. Hillerdal G, Henderson DW. Asbestos, asbestosis, pleural plaques and lung cancer. Scand J Work Environ Health. 1997;23(2):93-103.
99. Suzuki Y, Yuen SR, Ashley R. Short, thin asbestos fibers contribute to the development of human malignant mesothelioma: pathological evidence. Int J Hyg Environ Health. 2005;208(3):201-210.
100. Wong JYY, Rice C, Blair A, Silverman DT. Mesothelioma risk among those exposed to chrysotile asbestos only and mixtures that include amphibole: a case-control study in the USA, 1975-1980. Occup Environ Med. 2020; oemed-2020-106665.
101. Marsili D, Terracini B, Santana VS, Ramos-Bonilla JP, Pasetto R, Mazzeo A, et al. Prevention of asbestos-related disease in countries currently using asbestos. Int J Environ Res Public Health. 2016;13(5):494.
102. Kwak K, Kang D, Paek D. Environmental exposure to asbestos and the risk of lung cancer: a systematic review and meta-analysis. Occup Environ Med. 2022;79(3):207-214.
103. Carson M. From common market to social Europe? Acta Universitatis Stockholmiensis. Stockholm Studies in Sociology N.S. 2004; 22.
104. Tossavainen A, Kotilainen M, Takahashi K, Pan G, Vanhala E. Amphibole fibres in Chinese chrysotile asbestos. Ann Occup Hyg. 2001;45:145-152.
105. Bergamaschi E, Garzaro G, Wilson Jones G, Buglisi M, Caniglia M, Godono A, et al. Occupational exposure to carbon nanotubes and carbon nanofibres: more than a cobweb. Nanomaterials (Basel). 2021;11(3):745.
106. Gupta SS, Singh KP, Gupta S, Dusinska M, Rahman Q. Do carbon nanotubes and asbestos fibers exhibit common toxicity mechanisms? Nanomaterials (Basel). 2022;12(10):1708.
107. Bernstein DM, Toth B, Rogers RA, Kling DE, Kunzendorf P, et al. Evaluation of the dose-response and fate in the lung and pleura of chrysotile-containing brake dust compared to TiO2, chrysotile, crocidolite or amosite asbestos in a 90-day quantitative Inhal Toxicol study - Interim results Part 2: Histopathological examination, Confocal microscopy and collagen quantification of the lung and pleural cavity. Toxicol Appl Pharmacol. 2020;387:114847.
108. Thives LP, Ghisi E, Thives Júnior JJ, Vieira AS. Is asbestos still a problem in the world? A current review. J Environ Manage. 2022;319:115716.
109. Shanin NP, Borodulin MM, Kolbovsky YuYa, Krasovsky VN. Proizvodstvo asbestotekhnicheskikh izdeliy [Production of asbestos products]. Leningrad: Chemistry; 1983.
110. Vedernikov NN, Polyanin VS, Romanovich IF, Lisitsyn AE. Asbest. Moscow: Geoinformmark; 1999.
111. Jargin SV. Russian opinion on asbestos: All fibers equal. Environment and Ecology Research. 2013;1(2):79-83.
112. Culley MR, Zorland J, Freire K. Community responses to naturally occurring asbestos: implications for public health practice. Health Educ Res. 2010;25(5):877-891
